Skip to main content

Table 1 Summary of clinical and molecular-pathological characteristicsa

From: Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia

 

TOTAL

EGFR

KRAS

ALK

 

wt

mut

wt

mut

wt

mut

 

324 (100)

      

Age (range, median)

35-88, 63

      

Gender

 Male

194 (59.9)

183 (94.3)

11 (5.7)

97 (53.6)

84 (46.4)

80 (97.6)

2 (2.4)

 Female

130 (40.1)

90 (69.2)

40 (30.8)

61 (67.8)

29 (32.2)

40 (80.0)

10 (20.0)

Smoking status

 Smokers

147 (45.4)

139 (94.6)

8 (5.44)

75 (54.3)

63 (45.7)

65 (95.6)

3 (4.4)

 Former smokers

103 (31.8)

92 (89.3)

11 (10.7)

49 (53.8)

42 (46.2)

37 (97.4)

1 (2.6)

 Never-smokers

74 (22.8)

42 (56.8)

32 (43.2)

34 (81)

8 (19)

18 (69.2)

8 (30.8)

Clinical stageb

 I

26 (8.0)

22 (8.1)

4 (7.8)

8 (5.1)

11 (9.2)

7 (5.8)

0 (0)

 II-IIIA

63 (19.5)

51 (18.7)

12 (23.5)

31 (19.6)

20 (16.8)

28 (23.3)

1 (8.3)

 IIIB-IV

222 (68.5)

190 (69.6)

32 (62.7)

112 (70.9)

76 (63.9)

79 (65.8)

10 (83.3)

  1. Legend: adata presented as absolute numbers and percentages in parentheses; wt wild type, mut mutated, b for 12 patients no data for clinical stage were available; numbers in bold indicate a statistically significant difference